Health Canada has adopted the IMDRF Table of Contents (ToC) structure for medical device submissions, streamlining dossier preparation and supporting global regulatory convergence. The updated guidance outlines requirements for pre-market and post-market submissions and clarifies expectations for electronic filing, templates and documentation. Essential reading for manufacturers targeting the Canadian market.

Health Canada has released Phase II of its Medical Device Establishment Licensing (MDEL) Modernization Framework, introducing enhanced compliance expectations, strengthened oversight of foreign manufacturers, updated documentation requirements and a stronger focus on post-market safety. These changes are essential for manufacturers exporting medical devices to Canada.

A Health Canada publicou um relatório sobre a redução da burocracia regulamentar, destacando medidas para simplificar processos, reduzir custos e apoiar a inovação no setor da saúde. As iniciativas incluem digitalização de submissões, harmonização internacional e eliminação de requisitos redundantes, mantendo sempre a segurança dos pacientes como prioridade.

In January 2025, Health Canada published a new guide on the use of recognized standards to demonstrate compliance with the requirements of the Medical Devices Regulations. The document guides manufacturers in preparing submissions, updates and lifecycle management of applicable standards.

Health Canada has begun automatically canceling MDEL licenses for operators who have not complied with the mandatory annual review. The measure affects distributors and importers of medical devices in Canada and has serious consequences, such as interruption of operations, the need to resubmit license applications, and product retention.

Health Canada has announced new guidance for Risk Management Plans (RMPs), reinforcing the need for pharmacovigilance and risk minimization throughout the life cycle of medicines. As of April 2027, the submission of RMPs will be mandatory in certain circumstances, such as for new drugs, biosimilars and cases of emerging risks. This update harmonizes Canadian regulations with international standards, ensuring greater safety for patients and transparency in the regulatory process. Manufacturers wishing to market products on the Canadian market must adapt to these new requirements.